Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer

被引:20
作者
Tsutsui, Shinichi [1 ]
Yasuda, Kazuhiro
Suzuki, Kosuke
Takeuchi, Hideya
Nishizaki, Takashi
Higashi, Hidefumi
Era, Shoichi
机构
[1] Matsuyama Red Cross Hosp, Dept Breast Surg, Matsuyama, Ehime, Japan
[2] Beppu Med Ctr, Dept Surg, Beppu, Oita, Japan
[3] Beppu Med Ctr, Dept Pathol, Beppu, Oita, Japan
[4] Matsuyama Red Cross Hosp, Dept Surg, Matsuyama, Ehime, Japan
关键词
D O I
10.1186/1471-2407-6-187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recent experimental studies have shown that Bcl-2, which has been established as a key player in the control of apoptosis, plays a role in regulating the cell cycle and proliferation. The aim of this study was to investigate the relationship between Bcl-2 and p27 protein expression, p53 protein expression and the proliferation activity as defined by the MIB-1 counts. The prognostic implication of Bcl-2 protein expression in relation to p27 and p53 protein expressions and MIB-1 counts for breast cancer was also evaluated. Methods: The immunohistochemical expression of Bcl-2 protein was evaluated in a series of 249 invasive ductal carcinomas of the breast, in which p27 and p53 protein expressions and MIB-1 counts had been determined previously. Results: The Bcl-2 protein expression was found to be decreased in 105 (42%) cases. A decreased Bcl-2 protein expression was significantly correlated with a nuclear grade of III, a negative estrogen receptor, a decreased p27 protein expression, a positive p53 protein expression, positive MIB-1 counts and a positive HER2 protein expression. The incidence of a nuclear grade of III and positive MIB-1 counts increased as the number of abnormal findings of Bcl-2, p27 and p53 protein expressions increased. A univariate analysis indicated a decreased Bcl-2 protein expression to be significantly (p=0.0089) associated with a worse disease free survival (DFS), while a multivariate analysis indicated the lymph node status and MIB-1 counts to be independently significant prognostic factors for the DFS. Conclusion: The Bcl-2 protein expression has a close correlation with p27 and p53 protein expressions and the proliferation activity determined by MIB-1 counts in invasive ductal carcinoma of the breast. The prognostic value of Bcl-2 as well as p27 and p53 protein expressions was dependent on the proliferation activity in breast cancer.
引用
收藏
页数:7
相关论文
共 31 条
[1]   Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up [J].
Barbareschi, M ;
Caffo, O ;
Veronese, S ;
Leek, RD ;
Fina, P ;
Fox, S ;
Bonzanini, M ;
Girlando, S ;
Morelli, L ;
Eccher, C ;
Pezzella, F ;
Doglioni, C ;
Palma, PD ;
Harris, A .
HUMAN PATHOLOGY, 1996, 27 (11) :1149-1155
[2]   Control of proliferation by Bcl-2 family members [J].
Bonnefoy-Berard, N ;
Aouacheria, A ;
Verschelde, C ;
Quemeneur, L ;
Marcais, A ;
Marvel, J .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1644 (2-3) :159-168
[3]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[4]   Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers [J].
Chan, WY ;
Cheung, KK ;
Schorge, JO ;
Huang, LW ;
Welch, WR ;
Bell, DA ;
Berkowitz, RS ;
Mok, SC .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (02) :409-417
[5]   Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis [J].
Emi, Y ;
Kitamura, K ;
Shikada, Y ;
Kakeji, Y ;
Takahashi, I ;
Tsutsui, S .
SURGERY, 2002, 131 (01) :S217-S221
[6]   Low expression of bcl-2 in Brca1-associated breast cancers [J].
Freneaux, P ;
Stoppa-Lyonnet, D ;
Mouret, E ;
Kambouchner, M ;
Nicolas, A ;
Zafrani, B ;
Vincent-Salomon, A ;
Fourquet, A ;
Magdelenat, H ;
Sastre-Garau, X .
BRITISH JOURNAL OF CANCER, 2000, 83 (10) :1318-1322
[7]  
Fujieda S, 1999, INT J CANCER, V84, P315, DOI 10.1002/(SICI)1097-0215(19990621)84:3<315::AID-IJC20>3.3.CO
[8]  
2-L
[9]  
GASPARINI G, 1995, CLIN CANCER RES, V1, P189
[10]   BCL-xL and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases [J].
Greider, C ;
Chattopadhyay, A ;
Parkhurst, C ;
Yang, E .
ONCOGENE, 2002, 21 (51) :7765-7775